# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

> **NCT02622321** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 113 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Emicizumab
- **DRUG:** rFVIIa
- **DRUG:** aPCC

## Key facts

- **NCT ID:** NCT02622321
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-18
- **Primary completion:** 2016-10-25
- **Final completion:** 2020-12-01
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2021-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02622321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02622321, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02622321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*